As it is often assumed that delayed cerebral ischemia (DCI) after subarachnoid hemorrhage (SAH) is caused by vasospasm, clinical trials often focus on prevention of vasospasm with the aim to improve clinical outcome. However, the role of vasospasm in the pathogenesis of DCI and clinical outcome is possibly smaller than previously assumed. We performed a systematic review and metaanalysis on all randomized, double-blind, placebo-controlled trials that studied the effect of pharmaceutical preventive strategies on vasospasm, DCI, and clinical outcome in SAH patients to further investigate the relationship between vasospasm and clinical outcome. Effect sizes were expressed in pooled risk ratio (RR) estimates with corresponding 95% confidence intervals (CI). A total of 14 studies randomizing 4,235 patients were included. Despite a reduction of vasospasm (RR 0.80 (95% CI 0.70 to 0.92)), no statistically significant effect on poor outcome was observed (RR 0.93 (95% CI 0.85 to 1.03)). The variety of DCI definitions did not justify pooling the DCI data. We conclude that pharmaceutical treatments have significantly decreased the incidence of vasospasm, but not of poor clinical outcome. This dissociation between vasospasm and clinical outcome could result from methodological problems, sample size, insensitivity of clinical outcome measures, or from mechanisms other than vasospasm that also contribute to poor outcome.
Introduction
Delayed cerebral ischemia (DCI) is a common complication of aneurysmal subarachnoid hemorrhage (SAH). Delayed cerebral ischemia can be reversible or it may progress to cerebral infarction. Cerebral infarction is associated with poor clinical outcome and death (Rabinstein et al, 2004) . As vasospasm is strongly associated with DCI and clinical outcome, clinical trials in the last few decades focused on prevention of vasospasm with the aim to improve clinical outcome (Fergusen and Macdonald, 2007; Rosengart et al, 2007) . Progress has been made. Meta-analysis of population-based studies of aneurysmal SAH found that mortality decreased by 50% in the last 2 decades, mostly due to improved in-hospital care (Lovelock et al, 2010) . However, outcome remains poor, and some clinical trials designed to decrease vasospasm or DCI have not improved outcome after SAH (Macdonald et al, 2008) . One reason for this may be that the role of vasospasm in the pathogenesis of DCI and clinical outcome is smaller than previously assumed, although the role of drug side effects and insensitive outcome measures has not been ruled out (Kreiter et al, 2009) . To further investigate the relationship between vasospasm and clinical outcome, we pooled all randomized placebo-controlled trials that investigated pharmaceutical interventions as a preventive strategy in SAH patients.
Materials and methods
For this systematic review, the Cochrane Collaboration format was used (Higgins and Green, 2008) .
Selection Criteria
Types of studies: All randomized, double-blind, placebocontrolled trials that studied the efficacy of pharmaceutical strategies aiming to prevent vasospasm, DCI, and poor outcome in SAH patients were included, regardless of type and dosage of drug and follow-up duration.
Types of outcome measures: Only trials that included vasospasm, DCI, and clinical outcome as outcome events were included. Trials that did not report on all three outcome events were excluded. A sensitivity analysis was performed for studies that had angiographic vasospasm, and not vasospasm diagnosed by transcranial Doppler ultrasound (TCD), as an outcome measure.
Definition of outcome measures: Radiographic vasospasm was defined as a focal or generalized reduction of cerebral arterial caliber on catheter cerebral angiography or increased cerebral blood flow velocities on TCD. As the included studies used various definitions of angiographic and TCD vasospasm, we used the definitions used by the investigators of the original studies. If the investigators of the original studies categorized angiographic vasospasm into no/mild, moderate, and severe vasospasm, we used the number of patients who had moderate-to-severe vasospasm as an outcome event. Transcranial Doppler ultrasound vasospasm was defined as flow velocity of at least 120 cm/second or peak flow velocity of > 200 cm/ second. If studies reported on both angiographic and TCD vasospasm, the data on angiographic vasospasm was used for our analyses. Clinical deterioration due to DCI was defined as the occurrence of focal neurologic impairment (such as hemiparesis, aphasia, apraxia, hemianopia, or neglect) or a decrease of at least two points on the Glasgow coma scale (either on the total score or on one of its individual components (eye, motor on either side, verbal)), lasting for at least 1 hour, not apparent immediately after aneurysm occlusion, and not attributable to other causes by means of clinical assessment, computed tomography or magnetic resonance imaging scanning of the brain, and appropriate laboratory studies (Vergouwen et al, 2010b) . Poor clinical outcome was defined as severe disability, vegetative state, or death, as defined by the investigators of the individual studies, either measured with the modified Rankin Scale (mRS) or (extended) Glasgow Outcome Scale (GOS). If the investigators provided data on the individual categories of the used outcome scales, we considered a mRS of 3 to 6 or a GOS of 1 to 3 as poor clinical outcome. In those studies in which an inverted GOS was used, poor clinical outcome was readjusted to the original scale. For all included studies, we used data from the last blinded outcome measurement. If the study provided the percentage of patients with an outcome event, the actual numbers were calculated from the percentages.
Search strategy for identification of studies: Two of the authors (NE and MDIV) conducted a systematic search of the Pubmed database and the RefMan software (Thomson Reuters, Version 12, New York, NY, USA) up to March 2010 (week 9) for the variable 'SAH'. The search was limited to 'randomized trials' and 'human studies'. We also searched for additional studies in previous meta-analyses that investigated the efficacy of pharmaceutical interventions to prevent vasospasm and DCI.
Assessment of risk of bias: Two authors (NE and MDIV)
independently assessed risk of bias by reviewing methodological quality of the included studies for allocation concealment and blinding.
Statistics: Data were processed in Review manager 5.0.24, as supplied by the Cochrane Collaboration. Effect sizes were expressed in (pooled) risk ratio (RR) estimates. Statistical uncertainty was expressed in 95% confidence intervals (CI). Pooled data were interpreted to be heterogeneous in case the probability value of the w 2 -test was r0.20. If no heterogeneity could be demonstrated, we used a fixed-effects model. Otherwise a random-effects model was used. Funnel plots were made to investigate potential publication bias.
Results
The initial search yielded 733 articles, of which 697 were excluded after review of titles and abstracts. Publications were usually excluded because the study was not a randomized trial or it did not include the relevant outcome events. The remaining 37 studies were randomized, double-blind, placebocontrolled trials of pharmaceutical preventive strategies in patients with aneurysmal SAH, although some studies included patients with spontaneous SAH and no identified source of hemorrhage. Finally, 14 trials with 4,235 patients had radiographic vasospasm, DCI, and clinical outcome as outcome events and were included in the analysis (Chou et al, 2008; Findlay et al, 1995; Haley Jr et al, 1993a , b, 1997 Kassell et al, 1996; Macdonald et al, 2008; Neil-Dwyer et al, 1987; Ono et al, 1984; Petruk et al, 1988; Philippon et al, 1986; Shibuya et al, 1992; Springborg et al, 2007; Tseng et al, 2005 Tseng et al, , 2007 Vergouwen et al, 2009) . A total of 2,612 patients were randomized to pharmaceutical treatment and 1,623 patients to placebo. Funnel plots were not suggestive of publication bias (data not shown). Characteristics of the included studies are listed in the Table 1 . Vasospasm, DCI, 
Analyses
Of 14 studies eventually included in the metaanalysis, three reported on TCD vasospasm only (Springborg et al, 2007; Tseng et al, 2005; Vergouwen et al, 2009 ), five on both TCD and angiographic vasospasm (Chou et al, 2008; Haley et al, 1993b Haley et al, , 1997 Kassell et al, 1996; Macdonald et al, 2008) , five on angiographic vasospasm only (Findlay et al, 1995; Ono et al, 1984; Petruk et al, 1988; Philippon et al, 1986; Shibuya et al, 1992) , and in one study it was unclear (Neil-Dwyer et al, 1987) . For TCD vasospasm, various definitions and cutoff values were used for mean and peak blood flow velocity, with or without a Lindegaard ratio > 3 (Chou et al, 2008; Haley Jr et al, 1993b , 1997 Kassell et al, 1996; Macdonald et al, 2008; Springborg et al, 2007; Tseng et al, 2005; Vergouwen et al, 2009 ). In addition, for angiographic vasospasm, various definitions with different cutoff values and classifications for luminal narrowing and vasospasm severity were used (Table  1 ; Chou et al, 2008; Findlay et al, 1995; Haley Jr et al, 1993b , 1997 Kassell et al, 1996; Macdonald et al, 2008; Petruk et al, 1988; Philippon et al, 1986; Shibuya et al, 1992) . The definition of vasospasm was unclear in two studies (Neil-Dwyer et al, 1987; Ono et al, 1984) . For the analysis of radiographic vasospasm, data from 2,819 patients were available (1,783 patients randomized to pharmaceutical treatment and 1,036 to placebo). The overall number of patients with radiographic vasospasm was 634 in the group of patients randomized to pharmaceutical treatment and 516 in the placebo group. Our meta-analysis including 14 trial arms demonstrated a significant and favorable effect of treatment, compared with the placebo, on angiographic vasospasm (pooled RR 0.80; 95% CI, 0.70 to 0.92). Heterogeneity between the trials was high (I 2 = 62% and P = 0.001; Figure 1 ). This justified our use of the random-effects metaanalysis model. Regarding DCI, there was a wide variation of definitions (Table 1) . This variety of definitions did not justify pooling the DCI data.
For clinical outcome, most studies used the GOS (Findlay et al, 1995; Haley Jr et al, 1993a , b, 1997 Kassell et al, 1996; Macdonald et al, 2008; Petruk et al, 1988; Philippon et al, 1986; Shibuya et al, 1992; Springborg et al, 2007; Vergouwen et al, 2009) or mRS (Table 1; Chou et al, 2008; Tseng et al, 2005; Tseng et al, 2007) . One study used an inverted GOS (Philippon et al, 1986) . For the meta-analysis of poor clinical outcome, data from 4,211 patients were available (2,597 patients randomized to pharmaceutical treatment and 1,614 to placebo). The overall number of patients with poor outcome comprised 778 in the pharmaceutically treated group and 518 in the placebo group. Our meta-analysis including 14 trial arms did not show a significant effect of treatment, compared with the placebo, on poor clinical outcome (pooled RR 0.93; 95% CI, 0.85 to 1.03). Heterogeneity between the trials was not significant (I 2 = 9% and P = 0.36; Figure 2 ).
Sensitivity analysis:
In the sensitivity analysis that only included studies with angiographic vasospasm, and not TCD vasospasm, 10 studies were included with 3,994 patients. The pooled RR for angiographic vasospasm was 0.76 (95% CI 0.64 to 0.89) and for poor outcome 0.95 (95% CI 0.86 to 1.05).
Risk of Bias Assessment
For allocation concealment, risk of bias was low in seven studies (Haley Jr et al, 1993a, b; Macdonald et al, 2008; Petruk et al, 1988; Shibuya et al, 1992; Springborg et al, 2007; Tseng et al, 2005 Tseng et al, , 2007 Vergouwen et al, 2009) and unclear in seven studies (Table 1; Chou et al, 2008; Findlay et al, 1995; Haley Jr et al, 1997; Kassell et al, 1996; Neil-Dwyer et al, 1987; Ono et al, 1984; Philippon et al, 1986) . For Chou 2008 Findlay 1995 Haley 1993 Haley 1997 Kassell 1996 Macdonald 2008 Neil-Dwyer 1987 Ono 1984 Petruk 1988 Philippon 1986 Shibuya 1992 Springborg 2007 Tseng 2005 Vergouwen 2009 Total (95% CI) Total events Heterogeneity: Tau² = 0.04; Chi² = 34.43, df = 13 (P = 0.001); I² = 62% Test for overall effect: Z = 3.17 (P = 0.002) Figure 1 Pooled RR estimates for patients on pharmaceutical treatment found to have radiographic vasospasm. Vasospasm, DCI, and outcome N Etminan et al blinding, risk of bias was low in 11 studies (Findlay et al, 1995; Haley Jr et al, 1993a , b, 1997 Kassell et al, 1996; Macdonald et al, 2008; Ono et al, 1984; Petruk et al, 1988; Shibuya et al, 1992; Springborg et al, 2007; Tseng et al, 2005 Tseng et al, , 2007 Vergouwen et al, 2009) and unclear in 3 studies (Chou et al, 2008; Neil-Dwyer et al, 1987; Philippon et al, 1986) . High risk of bias was not observed in any of the studies. The authors of this systematic review acknowledge potential risk of bias, because they are authors of two of the studies included in this systematic review (Macdonald et al, 2008; Vergouwen et al, 2009 ).
Study or Subgroup

Discussion
This systematic review found that despite a decreased incidence of radiographic vasospasm, pharmaceutical treatment after SAH did not improve clinical outcome. A sensitivity analysis in which only those studies were included that had angiographic vasospasm as an outcome measure, and not TCD vasospasm, did not change our findings. The variety of definitions for clinical deterioration due to DCI did not justify pooling the DCI data.
Previous meta-analyses have questioned the relationship between vasospasm and clinical outcome (Dorhout Mees et al, 2007; Kramer and Fletcher, 2009; Zhang et al, 2010) . However, most of these analyses focused on classes of drugs, and therefore the results might be related to pharmacological properties of the type of drug studied. The present systematic review differs from previous studies because we pooled all studies that analyzed the effect of any pharmaceutical intervention, regardless of the type of drug (Weyer et al, 2006) . A systematic review that investigated the efficacy of the dihydropyridine calcium antagonist nimodipine showed that nimodipine reduces the incidence of DCI and improves clinical outcome without a statistically significant effect on vasospasm (Feigin et al, 1998) . Potential explanations are that, in the nimodipine studies confirmation of vasospasm was not obtained when DCI developed, or that nimodipine exerts its beneficial effect through profibrinolytic properties or conversion of cortical spreading ischemia to cortical spreading hyperemia (Dreier et al, 1998; Vergouwen et al, 2007) . Similar to the results of the present study, endothelin receptor antagonists reduced vasospasm and DCI, but not poor clinical outcome (Kramer and Fletcher, 2009 ). The effect of endothelin receptor antagonists on DCI is not unexpected as the included studies required radiographic confirmation of vasospasm in the diagnosis of DCI (Vergouwen, 2009) . Tirilazad mesylate reduced DCI, but not cerebral infarction and poor clinical outcome (Zhang et al, 2010) . Statin treatment had no effect on vasospasm, DCI, and clinical outcome (Vergouwen et al, 2010a) . However, the statin treatment metaanalysis included only 190 patients, which makes it difficult to draw definitive conclusions about efficacy of statins and their effects on vasospasm, DCI, and clinical outcome.
There are several explanations for the observed dissociation between radiographic vasospasm and clinical outcome in this meta-analysis. First, the pharmaceutical treatments for vasospasm could have detrimental effects that counterbalance any benefits that they might have on clinical outcome (Kramer and Fletcher, 2009) . Pulmonary complications, anemia, and hypotension occur more frequently after treatment with endothelin receptor antagonists and nicardipine, and these complications are independently associated with poor outcome (Kahn et al, 2006; Wartenberg et al, 2006) . In addition, rescue therapy such as the induction of hypervolemia and hypertension can lead to cardiovascular complications, possibly resulting in worse clinical outcomes. Balloon angioplasty for treatment of vasospasm can lead to complications such as arterial dissection, Study or Subgroup Chou 2008 Findlay 1995 Haley 1993 Haley 1997 Kassell 1996 Macdonald 2008 Neil-Dwyer 1987 Ono 1984 Petruk 1988 Philippon 1986 Shibuya 1992 Springborg 2007 Tseng 2005 Vergouwen 2009 Total (95% CI) Vasospasm, DCI, and outcome N Etminan et al rupture, stroke, and death. However, if rescue therapy or balloon angioplasty is actually effective, then it could obscure the beneficial effects of drug treatment by being used more in the placebo groups, and one would never show an association between prevention of vasospasm and outcome. Meta-analysis of trials of endothelin receptor antagonists found that these drugs increased side effects such as hypotension and pulmonary edema (Kramer and Fletcher, 2009 (Dreier et al, 2006; Vergouwen et al, 2008; Yundt et al, 1998) .
In the studies that were included in the present systematic review, many different definitions for clinical deterioration due to DCI were used, which did not justify to aggregate and pool the studies in a meta-analysis. Often, included studies combined radiographic evidence of vasospasm with clinical features of cerebral ischemia, while multiple factors might contribute to DCI. Recently, a uniform definition of DCI has been proposed with the aim to standardize end points for clinical trials, simplify comparisons between studies, and aggregate study results in meta-analyses (Vergouwen et al, 2010b) .
This study has some limitations. Angiography often was only performed in selected patients, a practice that would decrease the correlations among vasospasm, DCI, and clinical outcome. The definition and grading of radiographic vasospasm varied throughout the studies, and TCD as a diagnostic tool to measure vasospasm might add inaccuracy (Carrera et al, 2009 ). However, a sensitivity analysis that included studies with angiographic vasospasm only did not change the results. Finally, clinical outcome was measured with various scales and cutoffs for poor clinical outcome, and the timing of follow-up measurements differed among the included studies. However, these factors will have minimal effect because the GOS and mRS give almost identical results in patients with SAH (Macdonald et al, 2008) . The timing of outcome assessment only matters if there is a change in the rates of recovery in the treated and untreated groups, which seems unlikely given that the treatments being applied are in the acute stage.
In conclusion, pharmaceutical treatments may decrease radiographic vasospasm in patients with SAH, but there is no effect on the clinical outcome. Future studies need to determine whether this dissociation between vasospasm and clinical outcome is due to methodological problems, sample size, insensitivity of clinical outcome measures, the effect of therapeutic strategies such as endovascular therapy, or because of mechanisms other than vasospasm also contributing to poor clinical outcome.
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